ClinicalTrials.gg
RecruitingNCT07009704GEMS-PUpdated Nov 9, 2026

Glucose Empowerment Through Monitoring and Social Support in Pregnancy

An interventional study of Mobile-based social support and Real-time continuous glucose monitoring in Pregnancy, Complications and Gestational Diabetes, sponsored by Tufts Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionDiabetes, GestationalRegistry: Pregnancy ComplicationsReclassifiedWhy we changed it
Registry
Pregnancy Complications — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes, Gestational
Why
  1. The study's listed conditions name Diabetes, Gestational, a narrower term within Pregnancy Complications.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tufts Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.

Planned enrollment
106th of 194
70 · median 80
Started
2025
with 24 others
No phase
154 of 251
31 open now
Primary completion
2027-05
later than 40 of 64 live
Registered
224th of 251
by date

Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 106th largest by planned enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2025, is one of 154 with no phase, reaches primary completion later than 40 of the 64 other live ones, and was the 224th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Diabetes, Gestational with a site in United States, or all of them as a file.
02

Study summary

The purpose of the research is to learn whether wearing a continuous glucose monitor that shows blood glucose levels in real time on a smart phone app and participating in a group chat with other research participants will help participants keep a healthy blood glucose level during pregnancy.

High levels of blood glucose during pregnancy can lead to health problems during and after pregnancy. It may also increase the risk for health problems for the developing baby.

The investigators think our program might be a new way to help some people maintain a healthy blood glucose level during pregnancy. When pregnant people know their blood glucose levels are high, they can do things like exercise or drink water to bring their blood glucose levels down. They can also learn what foods to eat to maintain healthy blood glucose levels, and what foods to avoid. The investigators think being in a group chat with other pregnant individuals will allow participants to support and learn from each other. Pregnant individuals should also work with their healthcare providers to manage their blood glucose levels.

03

Conditions studied

  • Pregnancy, Complications
  • Gestational Diabetes

Browse trials for

Keywords

  • pregnancy
  • gestational diabetes
  • GDM
  • intervention
  • hyperglycemia
  • group chat
  • continuous glucose monitoring
  • mobile-based
  • behavioral change
  • CGM
04

In context

Diabetes, Gestational Reclassified

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

This study's planned enrollment of 70 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Tufts Medical Center is the lead sponsor of 200 studies on the registry; 27 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 16 (48%) have results posted.

Compared within Diabetes, Gestational, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pregnancy Complications. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant (\<20w0d)
  • At least 18 years to 45 years old
  • >25, personal history of GDM, or first-degree family member with type II diabetes
  • Comfortable conversing in English
  • Own a smartphone and willing to use the CGM app and Signal
  • Receiving prenatal care and planning to deliver at Tufts Medicine (Boston)
  • Signed the consent form
  • Currently located in the United States

Exclusion criteria

Exclusion Criteria:

  • Current pregnancy a multiple gestation (e.g., twins)
  • Smoked during this current pregnancy
  • Active hepatitis or infection
  • Current pregnancy have any documented fetal congenital anomalies
  • Current history of heroin, cocaine, crack, LSD, or methamphetamines
  • Current history of alcohol abuse
  • Previous gastric bypass
  • Shift work that alters the sleep/wake periods
  • Have known rheumatological or chronic inflammatory state (i.e., arthritis, inflammatory bowel disease)?
  • Chronic illnesses, including diabetes and dialysis, that require regular medication use
  • Uncontrolled hypothyroidism
  • Known culture of positive chorioamnionitis?
  • An adult who is unable to consent (e.g., cognitively impaired adults)
  • Ward of the state
  • Unable to read or write English
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Group 1- Group chat intervention

    Participants in group 1 will be randomized to wear a real-time continuous glucose monitor for 14 days and participate in a secure mobile-based group chat where they will provide and receive social support for glucose management. Participants will be in the group chat for 60 days.

    Behavioral: Mobile-based social support · Behavioral: Real-time continuous glucose monitoring

  • Experimental
    Group 2- No group chat intervention

    Participants in group 2 will be randomized to wear a real-time continuous glucose monitor for 14 days.

    Behavioral: Real-time continuous glucose monitoring

Interventions

  • BehavioralMobile-based social support

    Participants will be invited to join an encrypted group chat where they will be encouraged to provide and receive social support related to glucose management during early pregnancy. Other study participants and study team members will be in the group chat.

  • BehavioralReal-time continuous glucose monitoring

    Participants will receive a real-time continuous glucose monitor that pairs with an existing smartphone app that shows minute-by-minute glucose levels and records glucose levels in 5 minute increments.

07

What researchers measure

Primary outcomes

  1. Self-efficacy for glucose management

    Self-efficacy will be adapted from a validated survey of self-efficacy for type II diabetes management (DMSES UK)

    Time frame: Baseline, Day 3 of CGM, Day 7 of CGM, Day 14 of CGM, Day 60 of study

Secondary outcomes

  1. Motivation for glucose management

    Assessed using items from the Treatment Self-Regulation Questionnaire (TSRQ)

    Time frame: Baseline, Day 3 of CGM, Day 7 of CGM, Day 14 of CGM, Day 60 of study

  2. Pregnancy-specific stress

    Pregnancy-specific stress will be measured (via questionnaire) using a validated scale that was empirically associated with birth outcomes

    Time frame: Baseline, Day 60 of study participation

  3. Social support

    A social support survey was adapted from the validated Inventory of Socially Supportive Behaviors (ISSB) that assess multiple subtypes of social support (emotional, informational, instrumental/tangible, belonging, appraisal)

    Time frame: Baseline, Day 3 of CGM, Day 7 of CGM, Day 14 of CGM, Day 30 of group chat participation, Day 60 of study participation

  4. Pre-natal care satisfaction

    Prenatal care satisfaction will be assessed using a combination of questions from Raube and colleague's validated questionnaire and the Mother's Autonomy in Decision Making (MADM) scale. The combination of questionnaires is scored as "Excellent, Good, Average, Poor, N/A".

    Time frame: Baseline, Day 60 of study completion

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 22 months is below that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion May 2026 → May 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jun 8, 2025
StartActual
Jul 1, 2025
Primary completionEst.
May 2027was May 2026
CompletionEst.
Jul 2027was Jul 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→May 2027
Nov 9, 2026
Study completion
Jul 2026→Jul 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion May 2026→May 2027
    Study completion Jul 2026→Jul 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07009704
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jul 1, 2025
Primary completion
May 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Larissa Calancie, PhD
Contact
larissa.calancie@tufts.edu
(617) 636-0976

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion